Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
9 hedge funds and large institutions have $224K invested in Sonnet BioTherapeutics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
4% more capital invested
Capital invested by funds: $216K → $224K (+$7.61K)
0.45% more ownership
Funds ownership: 5.25% → 5.7% (+0.45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$17K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8.13K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$109 |
| 4 |
Raymond James Financial
St Petersburg,
Florida
|
+$7 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$4 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.4K |
| 2 |
Barclays
London,
United Kingdom
|
-$23 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MI
1
MMCAP International
Grand Cayman,
Cayman Islands
| $166K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $30.9K | +$109 | +87 | +0.4% |
|
|
XT
3
XTX Topco
George Town,
Cayman Islands
| $16.9K | +$17K | +13,668 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $8.26K | +$8.13K | +6,518 | +4,623% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1.82K | -$1.4K | -1,122 | -43% |
|
6
BlackRock
New York
| $81 | – | – | – |
|
|
CWA
7
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| $40 | – | – | – |
|
|
8
Bank of America
Charlotte,
North Carolina
| $36 | +$4 | +3 | +12% |
|
|
9
Raymond James Financial
St Petersburg,
Florida
| $7 | +$7 | +6 | New |
|
|
10
Barclays
London,
United Kingdom
| – | -$23 | -17 | Closed |
|
SONN Hedge Fund Activity: Q2 2025 in Review
9 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q2 2025, worth a combined $224K — up 3.5% from $216K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SONN positions and 1 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was XTX Topco, opening a new position worth an estimated $17K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.4K.
- 9 institutional investors held Sonnet BioTherapeutics (SONN) as of Q2 2025, up from 8 in Q1 2025.
- Funds reported $224K of Sonnet BioTherapeutics stock for Q2 2025, up 3.5% quarter-over-quarter.
- 2 funds opened new Sonnet BioTherapeutics positions in Q2 2025 and 1 closed out, a net change of +1 holder.
- The largest Sonnet BioTherapeutics buyer in Q2 2025 was XTX Topco, an estimated $17K added.
- The largest Sonnet BioTherapeutics seller in Q2 2025 was Tower Research Capital (TRC), an estimated $1.4K sold.
Based on aggregated 13F filings for Q2 2025.